Onconetix advanced another $500,000 to Realbotix, bringing the amount outstanding under the note to $3.0 million. The filing says the terms did not change and gives no new information about repayment, so it does not show a clear change in Onconetix's outlook.
The added loan ties up more Onconetix cash and leaves the company relying on Realbotix to repay it. The filing says the note's terms are unchanged and reports no repayment problem or outcome that shows the company's prospects have shifted.
Follow Onconetix, Inc. (ONCO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ONCO